The Ultimate Guide To Imipenem
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To guage various intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Primary trial aims had been to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis indiv